Who We Are
Lisata Therapeutics, which was formed from the merger of Caladrius Biosciences and Cend Therapeutics, is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.
Lisata was formed with the vision of combining the dynamic, creative, collaborative, and driven culture of a start-up environment with seasoned big pharma experience to develop innovative therapies based on clear differentiation and rigorous data applied in areas of high unmet medical need.
Lisata has assembled an experienced management team and Board of Directors with deep expertise in oncology and drug development. Additionally, we have engineered an efficient discovery engine by leveraging world-renown academic investigators and our internal expertise to identify new therapies for development.
We act in an honest, respectful, ethical manner
We are dedicated to shareholders, patients, physicians, and our teammates
We are tenacious and persevere in the face of challenges and adversity
We approach all that we do with drive, passion, and dedication
We are better, more effective and more efficient when we work together
We embrace opportunities to learn and develop